Latest long-term debt for SCPH: $53M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2025), SCPH shows a long-term debt of $53M. That compares with $40M in the prior-year period — up 33.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SCPH's long-term debt is now $53M (was $40M) — a 33.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether scPharmaceuticals is outperforming or lagging.
Tracking SCPH's long-term debt over time shows whether scPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $53M That compares with $40M in the prior-year period — up 33.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has scPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $53M) with ownership activity and broader fundamentals.
scPharmaceuticals's long-term debt is $53M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.